2 unknown. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
| Phase 2 | 2 | Unknown 2 |
Follow Other Solid Tumors: new trials by email Literature Review of Other Solid Tumors trials Research Report on Other Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors KD6001, Tislelizumab, Bevacizumab - Advanced HCC, Other Solid Tumors | Phase 1 / Phase 2 | Unknown | Shanghai Kanda Biotechnology Co., Ltd. | 85 | 2024-04-15 | 2024-01-10 |
| A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor GB263T - NSCLC, Other Solid Tumors | Phase 1 / Phase 2 | Unknown | Genor Biopharma Co., Ltd. | 120 | 2022-05-17 | 2022-08-05 |
Bevacizumab (1) · tislelizumab (1)
Genor Biopharma Co., Ltd. (1) · Shanghai Kanda Biotechnology Co., Ltd. (1)
Australia (1) · China (1)